Carmine Stengone, Pipeline Therapeutics CEO

J&J’s Janssen taps in­to Pipeline Ther­a­peu­tics’ neu­ro­science as­set for $50M up­front

John­son & John­son’s Janssen unit is delv­ing in­to the mus­carinic space with $50 mil­lion up­front for an oral Pipeline Ther­a­peu­tics as­set that will en­ter a Phase II in the sec­ond half of this year, CEO and pres­i­dent Carmine Sten­gone told End­points News.

The San Diego biotech test­ed its in­ves­ti­ga­tion­al com­pound, the mus­carinic M1 an­tag­o­nist PIPE-307, in two Phase I stud­ies and has gained an FDA go-ahead for a mid-stage study in pa­tients with re­laps­ing-re­mit­ting mul­ti­ple scle­ro­sis, or RRMS. Af­ter the Phase I stud­ies showed a “clean safe­ty pro­file,” Pipeline at­tract­ed “a fair bit of part­ner­ing in­ter­est,” with a few term sheets ne­go­ti­at­ed dur­ing the process, Sten­gone said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.